# US 2001/0027206 A1 · Method and composition for treating and preventing pathogenic effects caused by intracellular calcium overload

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0027206 A1
- Document ID: US20010027206A1
- Status: Published application
- Kind: A1
- Application number: 09/804,640
- Filed: 2001-03-12
- Published: 2001-10-04
- Earliest claimed: 1994-01-24
- Assignees: Leigh Biotechnology, Inc.
- Inventors: Robert D. Pearlstein; Richard S. Kramer
- Web page: https://patentgrep.com/patent/US20010027206A1

## CPC

- A61K 31/195: having an amino group
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a method and composition for treating or preventing pathogenic effects in a mammal caused by intracellular calcium overload, comprising administering to a mammal a mixture of sodium co-transport dependent amino carboxylic acids or their physiologically acceptable salts in an amount sufficient to substantially saturate sodium-dependent amino carboxylic acid transport mechanisms of a cell's plasma membranes. Administration of these amino carboxylic acids can advantageously treat or prevent cell lysis and irreversible cell damage caused by intracellular calcium overload, especially in mammals suffering from a disease condition associated with or resulting from insufficient tissue oxygenation.

## Claims

### Claim 1

A method for treating or preventing pathogenic effects in a mammal caused by intracellular calcium overload, comprising administering to the mammal a mixture of sodium co-transport dependent amino carboxylic acids or their physiologically acceptable salts in an amount sufficient to substantially saturate the sodium-dependent transport mechanisms of a cell's plasma membrane.

### Claim 2 (depends on 1)

The method of claim 1, wherein the mixture of amino carboxylic acids contain one or more substrates for a GLY transport system; one or more substrates for an A transport system; one or more substrates for an ASC transport system; one or more substrates for an N transport system; and at least one amino carboxylic acid stimulator of the mammal's hepatic urea cycle.

### Claim 3 (depends on 1)

The method of claim 1, wherein the mixture amino carboxylic acids are selected from the group consisting of alanine, proline, 2-aminoisobutyric acid, N-methyl-alpha-aminoisobutyric acid, glycine, arginine, cysteine, serine, glutamine, glutamic acid, histidine, and asparagine.

### Claim 4 (depends on 3)

The method of claim 3, further comprising an amino carboxylic acid capable of stimulating the mammal's hepatic urea cycle.

### Claim 5 (depends on 4)

The method of claim 4, wherein the amino carboxylic acid capable of stimulating the hepatic urea cycle is arginine.

### Claim 6 (depends on 3)

The method of claim 3, wherein the mixture of amino carboxylic acids is alanine, proline, histidine, serine, glycine, glutamine, glutamic acid, and arginine.

### Claim 7 (depends on 6)

The method of claim 6, wherein the mixture contains from about 7 to 34 g of alanine, from about 9 to 42 g of proline, from about 8 to 28 g of histidine, from about 8 to 34 g of serine, from about 7 to 38 g of glycine, from about 5 to 34 g of glutamine, from about 1 to 9 g of glutamic acid, and from about 6 to 58 g of arginine based on a one liter solution.

### Claim 8 (depends on 7)

The method of claim 7, wherein the mixture contains 30 g alanine, 35 g proline, 15 g histidine, 20 g serine, 32 g glycine, 21 g glutamine, 4 g glutamic acid, and 43 g arginine.

### Claim 9 (depends on 1)

The method of claim 1, wherein the step of administering further comprises an initial and a subsequent maintenance dosing of the mixture of amino carboxylic acids.

### Claim 10 (depends on 9)

The method of claim 9, wherein the initial dosing ranges from about 2 to 3 ml/kg of body weight given over about 30 minutes and the maintenance dosing ranges from about 1 to 2 ml/kg/hour.

### Claim 11 (depends on 8)

The method of claim 8, wherein said mixture of amino carboxylic acids is given in an initial dosage amount of 1.0 g/Kg of body weight over about 60 minutes and is given in a maintenance dosage amount of about 0.2 g/Kg/hour.

### Claim 12 (depends on 1)

The method of claim 1, wherein the amino carboxylic acid mixture is administered so as to attain a blood plasma concentration of about 300 milligrams or less total free amino carboxylic acid per deciliter of blood.

### Claim 13 (depends on 1)

The method of claim 1, wherein the amino carboxylic acids are administered so as to attain a blood plasma concentration of no less than about 200 milligrams total free amino carboxylic acid per deciliter of blood.

### Claim 14 (depends on 1)

The method of claim 1, further comprising administering one or more therapeutically active agents selected from the group consisting of a plasma extender, a water soluble magnesium salt, thrombolytic enzyme, a scavenger of toxic oxygen metabolites, a xanthine oxidase inhibitor, and a free iron binding substance.

### Claim 15

A pharmaceutical composition for treating or preventing pathogenic effects in a mammal caused by intracellular calcium overload comprising a mixture of sodium co-transport dependent amino carboxylic acids or their physiologically acceptable salts in an amount sufficient to substantially saturate the sodium-dependent transport mechanism of a cell's plasma membrane and treat or prevent said pathogenic effects, together with a pharmaceutically acceptable carrier.

### Claim 16 (depends on 15)

The composition of claim 15, further comprising one or more therapeutically active agents selected from the group consisting of a plasma expander, a water soluble magnesium salt, a thrombolytic enzyme, a scavenger of toxic oxygen metabolites, a xanthine oxidase inhibitor, and a free iron binding substance.
